Table 2 Liver weight/body weight (%) and liver TC and TG (mg/g) of the different sub-groups.

From: Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms

 

Liver weight/BW (%)

Liver TC

Liver TG

NC

2.25a ± 0.82

2.50a ± 0.14

5.10a ± 0.22

MC

3.74b ± 0.15

7.35b ± 0.21

14.60b ± 0.62

A

3.19c ± 0.04

4.95c ± 0.09

9.29c ± 0.26

N1

3.16c ± 0.06

6.74d ± 0.09

12.05d ± 0.22

NN1

3.18c ± 0.06

6.60d ± 0.11

12.15d ± 0.23

N2

3.58b ± 0.10

6.89bd ± 0.08

13.85b ± 0.31

NN2

3.56b ± 0.07

6.73d ± 0.14

14.55b ± 0.28

AN1

2.70d ± 0.08

4.28ef ± 0.37

7.66e ± 0.19

ANN1

2.73d ± 0.06

4.05e ± 0.2

7.51e ± 0.194

AN2

3.26c ± 0.11

4.71cf ± 0.09

9.21c ± 0.30

ANN2

3.16c ± 0.04

5.10c ± 0.22

9.59c ± 0.32

  1. Values are expressed as means ± SE (n = 8). Significance was considered at p < 0.05 within columns where different letters indicate statistical significance.
  2. NC control normal, MC metabolic syndrome control, A rats given atorvastatin drug, N1 rats received nutraceutical 1, NN1 rats treated with nutraceutical 1nanostructure, N2 rats received nutraceutical 2, NN2 rats given nutraceutical 2 nanostructure, AN1 rats taken atorvastatin drug with nutraceutical 1, ANN1 rats given atorvastatin drug with nutraceutical 1 nanostructure, AN2 rats treated with atorvastatin drug with nutraceutical 2, ANN2 rats received atorvastatin drug with nutraceutical 2 nanostructure, BW body weight, TC total cholesterol, TG triglycerides.
Back to article page